Published • loading... • Updated
WuXi Biologics Singapore CRDMO Hub Completes Modular Topping-Out of Drug Product Facility
The modular site will add 120,000 liters of capacity and is designed to produce about 100 million pre-filled syringes and vials a year.
- On Thursday, WuXi Biologics completed the topping out of its Drug Product facility at the Singapore CRDMO Hub, marking a key milestone toward the site's expected 2027 operational launch.
- Located on a 13.5-hectare site in Tuas Biomedical Park, the Hub will add 120,000 liters of manufacturing capacity to the Company's global network, reinforcing Singapore's position as a leading biopharmaceutical center.
- The facility targets an annual output of approximately 100 million units of pre-filled syringes and vials, utilizing advanced manufacturing lines and centralized Quality Control labs to meet international requirements.
- CEO Chris Chen stated the milestone reinforces the company's ability to provide a "resilient and geographically diversified supply chain," supporting global biopharmaceutical partners with world-class quality systems.
- Reflecting a commitment to Environmental, Social, and Governance standards, the facility incorporates green technologies like solar panels and advanced energy monitoring to ensure sustainable long-term business growth.
Insights by Ground AI
53 Articles
53 Articles
The Courier-Tribune+52 Reposted by 52 other sources
WuXi Biologics Singapore CRDMO Hub Completes Modular Topping-Out of Drug Product Facility
SINGAPORE, June 4, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has completed the topping out of the Drug Product (DP) facility at its Singapore CRDMO Hub (Hub). Once…
Coverage Details
Total News Sources53
Leaning Left9Leaning Right6Center20Last UpdatedBias Distribution57% Center
Bias Distribution
- 57% of the sources are Center
57% Center
L 26%
C 57%
R 17%
Factuality
To view factuality data please Upgrade to Premium
